Phase III PETALs Interim Analysis: Nilotinib ± PegIFN alfa-2a in Patients With Newly Diagnosed Ph-Positive CP CML

Slideset - Combining peginterferon-alfa 2a with nilotinib in patients with chronic-phase CML showed significantly better rates of deep molecular response than nilotinib alone.
Source: Clinical Care Options Leukemia - Category: Hematology Source Type: research